Published in Blood Weekly, May 12th, 1997
"Clinically, we have shown, in all the relevant target populations - coagulation factor deficient patients, pediatric patients, and patients requiring high doses of the product - this product is clinically indistinguishable from fresh frozen plasma [FFP], may have less toxicity, and certainly has all the advantages of being a standardized product," said Dr. Howard Grossberg, Vice President, Medical and Clinical Affairs, VITEX, New York, New York, at the Blood Safety & Screening Conference, sponsored by...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.